A subset analysis of DREAMM-8: outcomes for patients who received 1 prior LOT including lenalidomide
Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, comments on the results of a subset analysis of the DREAMM-8 study (NCT04484623), which investigated the efficacy of belantamab mafodotin (belamaf) plus pomalidomide and dexamethasone (Pd) versus bortezomib plus (Pd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). The patients in this subset analysis had received one prior line of therapy (LOT), which included lenalidomide. Dr Beksac highlights that the belamaf combination demonstrated a significant impact on progression-free survival (PFS), complete response (CR) rate, and measurable residual disease (MRD) negativity rate. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
